Immune Checkpoint Inhibitors: Clinical Trial Tracker

Description: Oncology market, for decades, has been pillar on three areas: Surgery, Radiation Therapy and Chemotherapy. Immuno-oncology, especially immune checkpoint inhibitors, has recently gained traction from several stakeholders. Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 inhibitor) was the first immune checkpoint inhibitor that was made commercially available in 2011 for treatment of patients suffering from unresectable or metastatic melanoma; it has enjoyed considerable success so far with annual sales of over USD 1 billion. The drug is currently being mirrored by various other drugs such as Opdivo, Keytruda, Empliciti and Tecentriq in clinical development.

The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform. The field has been abuzz with partnering activities; such collaborations provide a synergistic boom to both the partners in terms of enrichment of product portfolio, revenues and stability. Most common forms of partnerships include clinical trial collaborations, product licensing agreements, acquisitions and research collaborations.

In addition to the marketed drugs, we expect a number of drugs currently in advanced stages of development to achieve blockbuster status in the near future. The anticipated success of immune checkpoint inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants.

The primary objective of this report is to capture details on the various clinical trials that are currently underway in the field of immune checkpoint inhibitors. We have identified a number of immune checkpoint inhibitors and clinical trials that are either being conducted or planned to be conducted for each of these drugs.

For each specific product, we have provided the following information:

- Primary Drug
- Highest Phase of Development
- Manufacturer / Licensee
- Target Receptor
- Molecule Type
- Route of Administration

For each specific trial, we have provided the following information:

- Indication
- Therapeutic Area
- Type of Cancer
- Sponsor/Collaborator
- Trial Title
- Trial Objective
- Trial Phase
- Trial Status
- Start Date
- End Date
- Enrolment
- Age Group
- Age Range
- Gender
- Inclusion Criteria
- Exclusion Criteria
- Study Type
- Study Design
- Primary Endpoints
- Secondary Endpoints
- Other Endpoints
- Treatment Arm(s)
- Location(s)
- Primary Trial Identifier
- Other Identifiers
- Trial Results (if known)

The above information has also been presented in the form a dashboard to provide a high level quick overview of the ongoing activity in this space.

In addition to the clinical trial details, the report also provides the following:

Drivers and Restraints of the specific drug classes (CTLA-4 inhibitors, PD-1 / PDL-1 inhibitors and novel immune checkpoint inhibitors), wherein we have presented our opinion on the drivers and challenges associated with each of the drug class type.

Sales forecast of the immune checkpoint inhibitors market over the course of next ten years. Owing to the emerging nature of this market, we have presented three scenarios to add robustness to our market forecast. The conservative, base and optimistic scenarios represent three different tracks of industry evolution.

Research Methodology

The data presented in this report has been gathered via secondary research. The prime secondary sources of information include:

- Clinical trial registries
- Annual reports
- Investor presentations
- SEC filings
- Company websites
- Conference websites

Contents:

1. Market Overview
2. Dashboard: Pipeline and Trial Analysis
3. CTLA-4 Inhibitors: Trial Details
4. PD-1 Inhibitors: Trial Details
5. PDL-1 Inhibitors: Trial Details
6. Novel Immune Checkpoint Inhibitors: Trial Details
7. Molecules in Preclinical Development
8. Inclusion / Exclusion Criteria
9. Drivers and Restraints
10. Market Forecast: Assumptions
11. Market Forecast, 2016-2025

List of Figures

Figure 1 Immune Checkpoint Inhibitors in Clinical Development: Distribution by Highest Phase of Development
Figure 2 Immune Checkpoint Inhibitors in Clinical Development: Distribution by Target
Figure 3 Immune Checkpoint Inhibitors in Clinical Development: Distribution by Phase of Development and Companies
Figure 4 Immune Checkpoint Inhibitors in Clinical Development: Distribution by Type of Molecule
Figure 5 Immune Checkpoint Inhibitors in Clinical Development: Distribution by Key Players
Figure 6 Immune Checkpoint Inhibitors Clinical Trials: Distribution by Trial Phase
Figure 7 Immune Checkpoint Inhibitors Clinical Trials: Distribution by Trial Status
Figure 8 Immune Checkpoint Inhibitors Clinical Trials: Distribution by Sponsor Type
Figure 9 Immune Checkpoint Inhibitors Clinical Trials: Distribution by Tumor Type
Figure 10 Immune Checkpoint Inhibitors Clinical Trials: Distribution by Study Type
Figure 11 Immune Checkpoint Inhibitors Clinical Trials: Distribution by Gender Type
Figure 12 Immune Checkpoint Inhibitors Clinical Trials: Distribution by Molecule Type and Target
Figure 13 Immune Checkpoint Inhibitors Clinical Trials Design: Distribution by Allocation Type
Figure 14 Immune Checkpoint Inhibitors Clinical Trials Design: Distribution by Endpoint Classification
Figure 15 Immune Checkpoint Inhibitors Clinical Trials Design: Distribution by Interventional Model
Figure 16 Immune Checkpoint Inhibitors Clinical Trials Design: Distribution by Observational Model
Figure 17 Immune Checkpoint Inhibitors Clinical Trials Design: Distribution by Masking
Figure 18 Immune Checkpoint Inhibitors Clinical Trials Design: Distribution by Primary Purpose
Figure 19 Immune Checkpoint Inhibitors Clinical Trial Locations: Distribution by Continent
Figure 20 Immune Checkpoint Inhibitors Clinical Trial Locations: Distribution by G7 Countries
Figure 21 Immune Checkpoint Inhibitors Clinical Trial Locations: Distribution by EU5 Countries
Figure 22 Immune Checkpoint Inhibitors in Preclinical Development: Distribution by Companies

Drivers and Restraints

Figure A: CTLA-4 Inhibitors: Drivers and Restraints
Figure B: PD-1 and PDL-1 Inhibitors: Drivers and Restraints
Figure C: Novel Immune Checkpoint Inhibitors: Drivers and Restraints

Market Forecast Analysis

Figure A: Immune Checkpoint Inhibitors Market Forecast, 2016-2025

Pipeline Analysis

List Of Tables

Table A Companies Involved in the Development of Preclinical Immune Checkpoint Inhibitors

Pipeline Details

Table 1 CTLA-4 Inhibitors Clinical Development: Pipeline Details
Table 2 PD-1 Inhibitors Clinical Development: Pipeline Details
Table 3 PDL-1 Inhibitors Clinical Development: Pipeline Details
Table 4 Novel Immune Checkpoint Inhibitors Clinical Development: Pipeline Details
Table 5 Preclinical Development

Market Forecast Analysis

Table A Market Forecast: Assumptions

Ordering:
- Order Online - http://www.researchandmarkets.com/reports/3801997/
- Order by Fax - using the form below
- Order by Post - print the order form below and send to
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- **Product Name:** Immune Checkpoint Inhibitors: Clinical Trial Tracker
- **Web Address:** http://www.researchandmarkets.com/reports/3801997/
- **Office Code:** SCBREF1E

Product Formats
Please select the product formats and quantity you require:

- **Electronic (PDF) - Single User:** USD 949
- **Electronic (PDF) - Site License:** USD 1899
- **Electronic (PDF) - Enterprisewide:** USD 3499

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

- **Title:**
  - Mr
  - Mrs
  - Dr
  - Miss
  - Ms
  - Prof

- **First Name:** ____________________________  **Last Name:** ____________________________

- **Email Address:** *
  ____________________________

- **Job Title:**
  ____________________________

- **Organisation:**
  ____________________________

- **Address:**
  ____________________________

- **City:**
  ____________________________

- **Postal / Zip Code:**
  ____________________________

- **Country:**
  ____________________________

- **Phone Number:**
  ____________________________

- **Fax Number:**
  ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer:
Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World